A Randomized Phase 2 Trial of AM0010 in Combination with Pembrolizumab vs. Pembrolizumab Alone as First-line Therapy in Patients with Stage IV/Metastic Non-Small Cell Lung Cancer and Tumors with High Expression of PD-LI ≥ 50%

Project: Research project

Description

A Randomized Phase 2 Trial of AM0010 in Combination with Pembrolizumab vs. Pembrolizumab Alone as First-line Therapy in Patients with Stage IV/Metastic Non-Small Cell Lung Cancer and Tumors with High Expression of PD-LI ≥ 50%
StatusFinished
Effective start/end date5/1/1812/10/18

Funding

  • ARMO BIOSCIENCES, INC

Fingerprint

Non-Small Cell Lung Carcinoma
Neoplasms
Therapeutics
pembrolizumab